7 Top Gainers In Healthcare Sector (PTX, MYOV, DXR...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Pernix Therapeutics Holdings Inc. (PTX)

Pernix Therapeutics Holdings is the parent company of Pernix Therapeutics LLC, a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs, primarily for the U.S. market.

Gained 54.24% to close Wednesday's (Feb.13) trading at $1.82.

News: No news

Recent event:

On November 8, 2018, the Company reported third-quarter financial results.

Net loss was $11.8 million or $0.89 per share for the three months ended September 30, 2018, compared to net income of $6.4 million or $0.42 per share in the same period last year. Net revenues were $37.2 million for the third quarter of 2018, an 8% decrease from the $40.5 million in the third quarter of 2017.

The Company ended September 30, 2018, with cash and cash equivalents of $24.5 million.

2. BIOLASE Inc. (BIOL)

BIOLASE is a biomedical company developing dental lasers and dental imaging equipment.

Gained 25% to close Wednesday's trading at $2.25.

News: No news

Near-term Catalyst:

-- The Company is scheduled to release fourth quarter 2018 financial and operating results on March 5, 2019.

Net revenue for the third quarter of 2018 was $10.9 million, a slight increase from net revenue of $10.8 million in the year-ago same quarter. Net loss was $4.66 million or $0.23 per share in the third quarter of 2018 compared to a net loss of $4.61 million or $0.30 per share in the third quarter of 2017.

3. Constellation Pharmaceuticals Inc. (CNST)

Constellation Pharma is a clinical-stage biopharmaceutical company developing next-generation epigenetic treatments for cancer patients.

Gained 14.66% to close Wednesday's trading at $11.50.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase II trial of CPI-0610 in myelofibrosis, dubbed MANIFEST, is ongoing. interim data update of this trial is expected in Q2, 2019. -- A phase Ib/II trial of CPI-1205 in metastatic castration-resistant prostate cancer (mCRPC) in combination with either abiraterone or enzalutamide, dubbed ProSTAR, is underway. Data from phase Ib portion of the trial is anticipated in Q2, 2019, and interim phase II data of the ProSTAR trial is expected in the second half of 2019. -- A phase I study of CPI-0209 in solid tumors is expected to be initiated in mid-2019.

4. Cue Biopharma Inc. (CUE)

Cue Biopharma is an immunotherapy company.

Gained 13.85% to close Wednesday's trading at $6.00.

News: No news

Pipeline & Near-term Catalysts:

The lead candidate is Cue-101, which targets human papillomavirus (HPV)-associated cancers like head & neck cancer, and cervical cancer.

The Company expects to file an IND, seeking approval to commence phase I trial for Cue-101 in HPV-associated cancers, in the first quarter of 2019.

5. XOMA Corp. (XOMA)

XOMA is a biotechnology royalty aggregator, engaged in multiple and productive licensing agreements and development collaborations related to its antibody technologies.

Gained 13.82% to close Wednesday's trading at $14.33.

News: The Company announced that it has received a $5.5 million payment from Rezolute Inc., related to their 2017 license agreement, as most recently amended on January 7, 2019.

Near-term Catalyst:

The Company is expected to report its fourth quarter and full year 2018 financial results in the first week of March.

6. Myovant Sciences Ltd. (MYOV)

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases.

Gained 11.72% to close Wednesday's trading at $21.44.

News: No news

Clinical Trials:

Myovant's lead product candidate is Relugolix, under phase III development.

Relugolix is under five international Phase 3 clinical trials namely:

-- Two phase III trials in women with heavy menstrual bleeding associated with uterine fibroids, dubbed LIBERTY 1 & LIBERTY 2. -- Two phase III trials in women with endometriosis-associated pain, known as SPIRIT 1 & SPIRIT 2. -- A phase III trial in men with advanced prostate cancer, dubbed HERO.

Also in the pipeline is MVT-602, for the treatment of female infertility as part of assisted reproduction. This compound is under Phase 2a study in healthy women undergoing a controlled ovarian stimulation protocol.

Near-term Catalysts:

-- Top-line data from LIBERTY 1 phase III study is expected in Q2, 2019. -- Top-line results from phase IIa study of MVT-602 are expected to be reported in the first half of 2019. -- Top-line data from LIBERTY 2 phase III study is expected in Q3, 2019. -- Top-line data from HERO phase III study is expected in Q4, 2019. -- Enrollment in both SPIRIT 1 and SPIRIT 2 phase III trials is expected to be completed in Q1 2020.

7. Daxor Corporation (DXR)

The Company manufactures and markets FDA-cleared BVA-100 blood volume analyzer, which is used in conjunction with a single-use diagnostic kit.

Gained 11.71% to close Wednesday's trading at $18.99.

News: The Company will be sharing new data and how the BVA-100 can help guide fluid management to enhance treatment plans and individualize care at the Society for Critical Care Medicine (SCCM) 48th Congress at the San Diego Convention Center in San Diego, CA from February 17-19th, 2019.

New data published in the Journal of the American College of Cardiology - Heart Failure last October showed a reduction of 82% mortality and 56% reduced 30-day readmission rehospitalization in patients who received individualized treatment for acute heart failure guided by Daxor's BVA-100 Blood Volume Analyzer.